美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Russell Investments Core Plus Bond ETF

24.22

0.0000

成交量：7

成交額：169.87

市值：5,679.12萬

市盈率：- -

高：24.22

開：24.22

低：24.22

收：24.22

52周最高：25.19

52周最低：24.22

股本：234.50萬

流通股本：234.50萬

量比：0.20

換手率：0.00%

股息：0.23

股息率：0.93%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

「新新三樣」之中國創新藥：千億級BD背後的體系突圍

华夏时报网

【券商聚焦】華泰證券維持先聲藥業（02096）買入評級指新品放量及BD常態化

第十二批國採現場：多家金融機構到場介紹「集採貸」「BD貸」等服務產品

上半年BD交易破千億，創新藥長期趨勢向好？

專訪百奧賽圖沈月雷：「揭秘」一筆四個月就達成的BD合作

遼BD***、遼BF*、遼BT、遼B***，你被曝光了！大連為啥這麼做？

超百億資金悄悄買入這個賽道！

【券商聚焦】華泰證券維持翰森製藥(03692)買入評級指BD有望成常態化收入來源

半年BD狂飆千億、龍頭預增13倍！創新藥漲停潮再起

「BD紅利」進入兑現窗口創新藥企價值加速分化

「BD紅利」進入兑現窗口創新藥企價值加速分化

经济参考报

【券商聚焦】中信建投：創新藥企仍是高增長主線、BD交易持續催化業績

【券商聚焦】華源證券維持康諾亞-B(02162)買入評級指商業化與BD共振

【券商聚焦】國泰海通首予康諾亞-B(02162)買入評級指其商業化放量及BD兑現

19億美元！國產創新藥叒爆BD大單！港股通創新藥應聲反彈，520880摸高2.54%

港股通創新藥迅猛回血，520880衝高逾3%！BD史上最強半年度誕生，機構：中國創新藥從「可選」到「必選」

招商證券：國產創新藥BD出海持續活躍，海外藥企加大對中國優質資產的關注

【券商聚焦】中信證券：中國創新藥BD交易金額超預期增長即將進入密集數據催化期

信諾維IPO：2025年靠BD交易扭虧，杏澤興禾退出等引監管追問

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BD/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","market":"US","secType":"STK","nameCN":"Russell Investments Core Plus Bond ETF","latestPrice":24.218,"timestamp":1789569099616,"preClose":24.218,"halted":0,"volume":7,"delay":0,"changeRate":0,"floatShares":2345000,"shares":2345000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-16 12:36:27 EDT","open":24.218,"high":24.218,"low":24.218,"amount":169.874208,"amplitude":0,"askPrice":24.36,"askSize":100,"bidPrice":24.22,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":24.218,"nav":24.324847,"aum":57041766.42,"dividendRate":0.00932,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.2408,"preClose":24.218,"latestTime":"16:04 EDT","volume":2,"amount":48.436,"timestamp":1789502648572,"change":0.0228,"changeRate":0.000941,"amplitude":0},"volumeRatio":0.196222},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","floatShares":2345000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.196222,"shares":2345000,"dividePrice":0.2257,"high":24.218,"amplitude":0,"preClose":24.218,"low":24.218,"week52Low":24.218,"pbRate":"--","week52High":25.19,"institutionHeld":0,"latestPrice":24.218,"eps":0,"divideRate":0.00932,"volume":7,"delay":0,"ttmEps":0,"open":24.218,"prevYearClose":25.08,"prevWeekClose":24.249,"prevMonthClose":24.7551,"prevQuarterClose":25.19,"fiveDayClose":24.435,"twentyDayClose":24.735},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BD\",params:#limit:5,,,undefined,":[{"date":"2026-09-02","symbol":"BD","amount":0.104028,"announcedDate":"2026-09-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-02","defaultRemindTime":1788355800000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-04","payableDate":"2026-09-02","currency":"USD","dateTimestamp":1788321600000,"payDate":"2026-09-04"},{"date":"2026-08-04","symbol":"BD","amount":0.120736,"announcedDate":"2026-08-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-04","defaultRemindTime":1785850200000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-06","payableDate":"2026-08-04","currency":"USD","dateTimestamp":1785816000000,"payDate":"2026-08-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BD\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-04","recordDate":"2026-08-04","paymentDate":"2026-08-06","value":0.120736,"currency":"USD"},{"executeDate":"2026-09-02","recordDate":"2026-09-02","paymentDate":"2026-09-04","value":0.104028,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BD\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656374770","title":"「新新三樣」之中國創新藥：千億級BD背後的體系突圍","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374770","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656374770?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 21:33","pubTimestamp":1785763991,"startTime":"0","endTime":"0","summary":"今年以来，中国制造出海出现了越来越多新面孔。前两年，电动载人汽车、锂电池、太阳能电池被称为出口“新三样”，而今年上半年，机器人、人工智能、创新药成为未来产业方向的“新新三样”。数据显示，中国创新药企2026年上半年的海外授权（BD）交易总额，逼近2025年全年1357亿美元的七成，较2024年更是近乎翻倍。然而，比这一惊人数字更值得关注的，是交易结构的深层质变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033830056118.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033830056118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656322031","title":"【券商聚焦】華泰證券維持先聲藥業（02096）買入評級 指新品放量及BD常態化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656322031","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656322031?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 17:18","pubTimestamp":1785748719,"startTime":"0","endTime":"0","summary":"在行业波动背景下，公司超预期的业绩表现展现了新品种的强烈市场需求及高管变动后的效率提升，同时BD的常态化有望带来持续新增量。预计全年内生业务维持中报预告趋势，利润端受益于BD将继续跨越式提升。此外，在SIM0709年初实现BD及SIM0500后续潜在里程碑等带动下，预计公司合作收入将步入常态化，带来持续的收入增量。TCE平台SIM0500的I期数据有望年内读出，TOPOi毒素ADC平台已通过SIM0613和SIM0505的BD出海得到全面验证。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","BD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655335512","title":"第十二批國採現場：多家金融機構到場介紹「集採貸」「BD貸」等服務產品","url":"https://stock-news.laohu8.com/highlight/detail?id=2655335512","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655335512?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 10:46","pubTimestamp":1785465967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4211","FISI","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655247857","title":"上半年BD交易破千億，創新藥長期趨勢向好？","url":"https://stock-news.laohu8.com/highlight/detail?id=2655247857","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655247857?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 16:08","pubTimestamp":1785312480,"startTime":"0","endTime":"0","summary":"2026年以来，创新药指数较年初有一定调整，有机构认为，这主要受阶段性行业偏好变化等市场因素影响。2026年上半年全球医药交易前十大事件中，中国药企占据八席。据东方证券统计，2026年BD交易的平均首付款和平均交易金额分别达0.6亿美元和10.6亿美元，同比分别增长38%和22%。机构表示，此举有望提升国产创新药临床可及性。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-29/doc-iniknezp2657599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","06978","BK1161","BK1574","BD","LNGR","IBBQ","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653758618","title":"專訪百奧賽圖沈月雷：「揭秘」一筆四個月就達成的BD合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653758618","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653758618?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 16:15","pubTimestamp":1784708100,"startTime":"0","endTime":"0","summary":"　　从双方正式启动合作到完成协议签署，历时仅仅约四个月，回顾百奥赛图与纳斯达克上市公司Whitehawk Therapeutics的BD合作，整个项目推进速度远快于行业同类项目。百奥赛图董事长兼CEO沈月雷博士在接受动脉网访谈时如此评价。　　据了解，近日百奥赛图与Whitehawk Therapeutics， Inc．宣布双方已签署一项全球战略合作协议，涵盖多个双特异性抗体偶联药物研发项目，双方将共同推进多元化的新一代治疗产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/enterprise/cn/2026-07-22/doc-iniisiee8049992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688796","BK0216","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653237792","title":"遼BD*****、遼BF*****、遼BT****、遼B*****，你被曝光了！大連為啥這麼做？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653237792","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653237792?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 11:44","pubTimestamp":1784605440,"startTime":"0","endTime":"0","summary":"辽望观天下）最近，大连对出租车行业刚柔并济的管理，收获“大赞”。大连同步推出“的哥的姐说大连，城市故事传四方”活动，鼓励司机为外来乘客讲城市历史、风土人情。不回避服务乱象、主动滋养行业荣誉感，内外兼修，才能让城市口碑行稳致远。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-07-21/doc-iniiptrh9371401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652968292","title":"超百億資金悄悄買入這個賽道！","url":"https://stock-news.laohu8.com/highlight/detail?id=2652968292","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652968292?lang=zh_tw&edition=fundamental","pubTime":"2026-07-20 18:20","pubTimestamp":1784542804,"startTime":"0","endTime":"0","summary":"发生了什么？","market":"sg","thumbnail":"https://img3.gelonghui.com/3b82f-545adabe-fec1-4670-a0b5-27a6cec8d77f.jpg?guru_height=2611&guru_width=4570&guru_size=1374188","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/3b82f-545adabe-fec1-4670-a0b5-27a6cec8d77f.jpg?guru_height=2611&guru_width=4570&guru_size=1374188"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5653295","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4550","159938","BD","FDN","BK4585","MEDX","BK1161","560260","603127","BK1576","BK4588","BK1141","06127","513120","515120","IBBQ","06978","BK1574","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651414441","title":"【券商聚焦】華泰證券維持翰森製藥(03692)買入評級 指BD有望成常態化收入來源","url":"https://stock-news.laohu8.com/highlight/detail?id=2651414441","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651414441?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 15:31","pubTimestamp":1784187092,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券发布研报指，翰森制药 核心产品HS-20118通过授权合作，有望深度分享其全球价值。公司已于2026年6月将HS-20118的大中华区外权益授予Avere，据此有望获得1.2亿美元首付款、最高21.8亿美元里程碑付款及中个位数至低双位数百分比的销售分成。华泰证券认为，BD已开始陆续贡献里程碑收入，有望成为公司的常态化收入及利润来源，维持“买入”评级。主要风险包括临床试验进展不及预期、产品价格下滑及海外BD进展缓慢。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986020","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BD","03692","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651879434","title":"半年BD狂飆千億、龍頭預增13倍！創新藥漲停潮再起","url":"https://stock-news.laohu8.com/highlight/detail?id=2651879434","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651879434?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 13:50","pubTimestamp":1784094601,"startTime":"0","endTime":"0","summary":"政策密集加码","market":"sh","thumbnail":"https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5584162","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0239","600664","002317","BK0060","688192","BK0077","159992","BK0070","300149","BK0216","BK0012","BK1161","000566","BK1574","MEDX","IBBQ","BK0188","BK0146","002940","BD","06978","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651482441","title":"「BD紅利」進入兑現窗口 創新藥企價值加速分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2651482441","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651482441?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 07:28","pubTimestamp":1784071736,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BD","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651481540","title":"「BD紅利」進入兑現窗口 創新藥企價值加速分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2651481540","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651481540?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 04:37","pubTimestamp":1784061458,"startTime":"0","endTime":"0","summary":"持续升温的创新药海外授权交易（以下简称“创新药BD”）正进入价值兑现窗口。近日，石药集团（01093.HK）发布公告称，公司于7月10日收到阿斯利康支付的2500万美元研发里程碑付款。此前，公司已于5月29日收到该BD协议项下首付款12亿美元。对此，业内人士表示，2026年以来，中国创新药BD交易开始从“规模出海”迈向“价值出海”，进入常态化、高质量增长的新周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153806272733.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153806272733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1574","IBBQ","BK1161","BD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：創新藥企仍是高增長主線、BD交易持續催化業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651568164?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","601066","LU1961090484.USD","LU0348735423.USD","01177","LU0455707207.USD","01877","01093","KURE","LU2097828631.EUR","LU1813983027.USD","LU0501845795.SGD","01801","09995","IE00B0JY6N72.USD","LU0456846285.SGD","BK1161","02142","BK1588","LU0051755006.USD","IE0008368742.USD","02616","IBBQ","KCE","LU0516422366.SGD","LU1960683339.HKD","LU0067412154.USD","06160","LU2242644610.SGD","09688","LU1969619763.USD","LU0359201612.USD","06978","BK1515","IE0008369823.USD","LU2097828474.EUR","LU1807302812.USD","02269","LU1993786604.SGD","LU1688375341.USD","LU0359202008.SGD","BD","LU2488822045.USD","MEDX","IE00B5MMRT66.SGD","159992","06185","LU0348825331.USD","LU1226288170.HKD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907376","title":"【券商聚焦】華源證券維持康諾亞-B(02162)買入評級 指商業化與BD共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907376","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650907376?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 14:39","pubTimestamp":1783665555,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华源证券发布研报指，康诺亚-B 正迈入商业化放量与BD收益兑现的共振阶段，2026年下半年多项关键催化剂值得期待。首先，CMG901若于2026年下半年向美国FDA申报并于2027年进入商业化，公司将在收到6300万美元首付款的基础上，逐步兑现总额超11亿美元的潜在里程碑及销售分成，持续增厚业绩。华源证券预计公司2026-2028年归母净利润分别为11.67/0.59/5.50亿元。考虑到公司商业化放量可期，伴随着商业化进程持续推进，BD收益有望逐步兑现，维持“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985582","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","KCE","02162","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907306","title":"【券商聚焦】國泰海通首予康諾亞-B(02162)買入評級 指其商業化放量及BD兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907306","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650907306?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 14:30","pubTimestamp":1783665009,"startTime":"0","endTime":"0","summary":"对外合作方面，CM336通过NewCo模式完成从资产授权到被吉利德科学以21.75亿美元整体收购的闭环，康诺亚作为Ouro股东已收到2.57亿美元首付款，跑通BD价值兑现路径。采用DCF估值法，给予目标价120.85元人民币，折合138.91港元，首次覆盖给予“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985587","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BD","02611","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650091029","title":"19億美元！國產創新藥叒爆BD大單！港股通創新藥應聲反彈，520880摸高2.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650091029","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650091029?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 10:38","pubTimestamp":1783564680,"startTime":"0","endTime":"0","summary":"创新药BD出海再添大单！中国生物制药最新公告，将旗下PDE3/4抑制剂TQC3721授予阿斯利康中国以外地区独家许可，首付款2亿美元，开发、监管及销售里程碑合计最高可达19亿美元，另享最高双位数百分比的分级特许权使用费。　　二级市场火速响应，7月9日早盘，中国生物制药高开高走，一度涨超6%，所在港股通创新药板块大面积回暖，100%布局创新药研发龙头的港股通创新药ETF华宝摸高2．54%，截至发稿涨0．92%，成交超4亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-09/doc-inihenaz1477348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","IBBQ","BK1574","MEDX","FLHK","520880","BD","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649951643","title":"港股通創新藥迅猛回血，520880衝高逾3%！BD史上最強半年度誕生，機構：中國創新藥從「可選」到「必選」","url":"https://stock-news.laohu8.com/highlight/detail?id=2649951643","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649951643?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 10:10","pubTimestamp":1783476600,"startTime":"0","endTime":"0","summary":"7月8日早盘，港股通创新药迅猛“回血”！龙头股信达生物、康方生物反弹2．5%，中国生物制药大涨6%。100%创新药研发标的——港股通创新药ETF华宝高开后一度上探3．2%，现涨2．29%，成交超2．5亿元。　　消息面，2026年上半年，中国创新药海外授权交易总额高达997亿美元，创史上最强半年度！　　国金证券指出，这标志着中国创新资产从“可选”变为“必选”，估值体系正从国内向全球接轨。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-08/doc-inihaawc1478480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD","BK1574","IBBQ","520880","BK1161","FLHK","06978","159992","KURE","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649627484","title":"招商證券：國產創新藥BD出海持續活躍，海外藥企加大對中國優質資產的關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2649627484","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649627484?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 22:29","pubTimestamp":1783348195,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0276","BK1564","BK1161","600999","BD","IBBQ","MEDX","BK1574","06978","BK0028","BK0183","BK1147","06099","159992","BK0188","BK0012","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646840322","title":"【券商聚焦】中信證券：中國創新藥BD交易金額超預期增長 即將進入密集數據催化期","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840322","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646840322?lang=zh_tw&edition=fundamental","pubTime":"2026-06-25 09:03","pubTimestamp":1782349398,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研报指，2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看，头部创新药企业在新产品驱动下，创新药收入快速增长，Biopharma陆续进入盈利拐点。研报认为创新药产业全球价值凸显，接下来将进入密集数据催化期。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984448","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","01177","01877","BK0028","LU2328871848.SGD","06030","01093","SG9999004220.SGD","LU1813983027.USD","LU0501845795.SGD","01801","09995","IE00B0JY6N72.USD","IE00BZ08YT58.USD","LU2289578879.USD","02142","SG9999002562.SGD","IE0008368742.USD","02616","LU1328277881.USD","LU1960683339.HKD","IE00B031HY20.USD","06160","LU0181495838.USD","LU1226288253.USD","09688","LU1064130708.USD","LU1997245094.SGD","06978","LU0540923850.HKD","LU2097828474.EUR","02269","600030","LU0856984785.SGD","LU0405327148.USD","BK0196","BK1574","BD","LU0359202008.SGD","LU0348767384.USD","LU1242518857.USD","LU2039709279.SGD","IE00B5MMRT66.SGD","LU0823426480.USD","LU1794554557.SGD","159992","06185","LU0327786744.USD","SG9999002463.SGD","BK1610"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645168867","title":"信諾維IPO：2025年靠BD交易扭虧，杏澤興禾退出等引監管追問","url":"https://stock-news.laohu8.com/highlight/detail?id=2645168867","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645168867?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 14:47","pubTimestamp":1782283624,"startTime":"0","endTime":"0","summary":"中国网财经6月24日讯 根据上交所安排，苏州信诺维医药科技股份有限公司 IPO将于6月26日上会，计划募集资金29.4亿元，其中6亿元补充流动资金，其余投向新药研发项目。　　资料显示，信诺维成立于2017年，是一家创新药公司。截至招股说明书签署日，信诺维针对抗肿瘤、抗感染等多个重大疾病领域，开发了10款主要在研创新药管线，其中注射用亚胺西福预计于2026年上市。　　2022年8月，杏泽兴禾把持有的信诺维股份进行了转让。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202606/24/20260624569914.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202606/24/20260624569914.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260624/32288256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","BD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":39,"code":"91000000","status":"200"}]}}